Human T-cell leukemia virus type 1 (HTLV-1) (HTLV-1)

Human T-cell leukemia virus type 1 (HTLV-1) is a complex retrovirus that infects approximately 5 to 10 million people worldwide, primarily targeting CD4+ T-lymphocytes (Gessain & Cassar, 2012). The Jurkat cell line, derived from human T-cell leukemia, serves as a critical laboratory model for studying the molecular mechanisms of HTLV-1 infection, particularly the role of the viral transactivator protein Tax in driving oncogenesis (Grassmann et al., 2005). HTLV-1 infection can lead to Adult T-cell leukemia/lymphoma (ATL) or HTLV-1-associated myelopathy (HAM/TSP), diseases characterized by high morbidity and limited treatment options (Bangham et al., 2019). Therapeutic interventions often target the viral life cycle using reverse transcriptase inhibitors like Zidovudine or focus on the malignant phenotype using monoclonal antibodies such as Mogamulizumab, which targets the CCR4 receptor (Ishida et al., 2012). Because 'HTLV-1 infection in Jurkat cells' refers to an experimental model of disease progression rather than a single protein or receptor, it is classified as a biological system used for drug discovery rather than a discrete therapeutic target.

Other names

HTLV-IHuman T-lymphotropic virus type 1HTLV-1 infection model

Reverse transcriptase inhibition, Immunomodulation, Antibody-dependent cellular cytotoxicity (ADCC), Proteasome inhibition (Ishida et al., 2012; Bangham et al., 2019).